Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Current Alzheimer research - 1 May 2012

Troquier Laetitia, Caillierez Raphaelle, Burnouf Sylvie, Fernandez-Gomez Francisco J, Grosjean Marie-Eve, Zommer Nadege, Sergeant Nicolas, Schraen-Maschke Susanna, Blum David, Buee Luc

Abstract excerpt

Recent data indicate that Tau immunotherapy may be relevant for interfering with neurofibrillary degeneration in Alzheimer disease and related disorders referred to as Tauopathies. The key question for immunotherapy is the choice of the epitope to target. Abnormal phosphorylation is a well-described post-translational modification of Tau proteins and may be a good target. In the present study, we investigated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Cognition Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme-Linked Immunosorbent Assay

Share to Hippocampus

Share to Maze Learning

Share to Peptides

Share to Serine

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 22272619
DOI: 10.2174/156720512800492503
PMCID: PMC3637173

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.PMID 22272619Read ↗

Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.Semantic proximity Read ↗

Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice.Semantic proximity Read ↗

THY-Tau22 mouse model accumulates more tauopathy at late stage of the disease in response to microglia deactivation through TREM2 deficiencySemantic proximity Read ↗

Tau‐targeting passive immunization modulates aspects of pathology in tau transgenic miceSemantic proximity Read ↗

Elevated levels of soluble total and hyperphosphorylated tau result in early behavioral deficits and distinct changes in brain pathology in a new tau transgenic mouse model.Semantic proximity Read ↗

Characterization of a Mouse Model of Alzheimer's Disease Expressing Aβ4-42 and Human Mutant Tau.Semantic proximity Read ↗

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy ModelsSemantic proximity Read ↗

Progressive Age-Related Cognitive Decline in Tau MiceSemantic proximity Read ↗

Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.Semantic proximity Read ↗

In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510Semantic proximity Read ↗

Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40.Semantic proximity Read ↗

Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.